+86-28-82633860 sales@biopurify.com 

Salvianolic acid A

CAS No.:96574-01-5

Salvianolic acid A
Catalogue No.: BP1247
Formula: C26H22O10
Mol Weight: 494.452
+86-28-82633860 +86-18080483897
Email me
Product name: Salvianolic acid A
Synonym name: 
Catalogue No.: BP1247
Cas No.: 96574-01-5
Formula: C26H22O10
Mol Weight: 494.452
Botanical Source: Salviae Miltiorrhizae Radix et Rhizoma
Physical Description: Powder
Type of Compound: Stibene glucosides

Purity: 95%~99%
Analysis Method: HPLC-DAD or/and HPLC-ELSD
Identification Method: Mass, NMR
Packing: Brown vial or HDPE plastic bottle

Storage: Store in a well closed container, protected from air and light. Put into refrigerate or freeze for long term storage.
Whenever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20℃. Generally, these will be useable for up to two weeks.

The product could be supplied from milligrams to grams, up to kilograms
Inquire for bulk scale.

Salvianolic acid A (SAA), the water-soluble phenolic acids in Salvia miltiorrhiza, has protection against cerebral lesion, defense from oxidative damage and improvement of remembrance; it also has antithrombotic effect, antiplatelet action and can modulate hemorheology without affecting coagulation system, the mechanisms underlying such activities may involve the induction of cAMP.[1]
Salvianolic acid A possesses antioxidant activity, also has a significant protective effect against isoproterenol-induced myocardial infarction; it activates the Nrf2/HO-1 axis in RPE cells and protects against oxidative stress via activation of Akt/mTORC1 signaling. [2,3]
Salvianolic acid A (oral) can significantly improve glucose metabolism and inhibit oxidative injury as well as protect against impaired vascular responsiveness in STZ-induced diabetic rats.[4]
Salvianolic acid A has protection on oxidative stress and liver injury induced by carbon tetrachloride in rats, which may mainly be related to its antioxidative effect.[5
Salvianolic acid A inhibits platelet activation via the inhibition of PI3K, and attenuates arterial thrombus formation in vivo, suggests that SAA may be developed as a novel therapeutic agent for the prevention of thrombotic disorders.[6]
Salvianolic acid A is a novel matrix metalloproteinase-9 inhibitor, can prevents cardiac remodeling in spontaneously hypertensive rats.[7]
Salvianolic acid A inhibits PDGF-BB-activated HSC proliferation, partially through apoptosis induction, it exerts no direct cytotoxicity on primary hepatocytes and HSC-T6 cells under experimental concentrations. [8]

[1] Fan H, Fu F, Yang M, et al. Thromb Res, 2010, 126(1):17-22.
[2] Wang S B, Tian S, Fan Y, et al. Eur J Pharmacol, 2009, 615(1-3):125-32.
[3] Zhang H, Liu Y Y, Jiang Q, et al. Free Radical Biol Med, 2014, 69(4):219-28.
[4] Wang S B, Yang X Y, Tian S, et al. Life Sci, 2009, 85(13–14):499-504.
[5] Wu Z M, Wen T, Tan Y F, et al. Basic Clinl Pharmacol Toxicol, 2007, 100(2):115-20.
[6] Z. S. HUANG ?, C. L. ZENG ?, Zhu L J, et al. J Throm Haemost, 2010, 8(6):1383-93.
[7] Jiang B, Li D, Deng Y, et al. Plos One, 2013, 8(3):e59621-e59621.
[8] Lin Y L, Lee T F, Huang Y J, et al. J Pharm Pharmaco, 2006, 58(7):933-9.
[9] Wang Z, Xu Y, Jiao R, et al. China Pharmacist, 2014(09):1473-5.